Afamelanotide

DERMATOLOGICALS

Key facts

Afamelanotide is a drug catalogued in DrugCentral. It was first approved by the EMA in 2014. DrugCentral lists 9 molecular targets, including Mc1r, Mc5r and Mc3r. Recorded indications include Erythropoietic protoporphyria.

• Molecular targets: Mc1r, Mc5r, Mc3r and MC1R (9 listed in DrugCentral).
• Indications: Erythropoietic protoporphyria.
• ATC code: D02BB02 (Protectives against UV-radiation for systemic use).
• Molecular formula: C78H111N21O19; molecular weight 1646.87 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Erythropoietic protoporphyria

Mechanism & targets

Molecular targets (9)

Target	Gene	Action	Activity
Melanocyte-stimulating hormone receptor	Mc1r	unknown	EC50 11.00
Melanocortin receptor 5	Mc5r	unknown	EC50 10.15
Melanocortin receptor 3	Mc3r	unknown	EC50 10.15
Melanocyte-stimulating hormone receptor	MC1R	agonist	IC50 10.00
Melanocortin receptor 4	Mc4r	unknown	EC50 9.92
Melanocortin receptor 5	MC5R	agonist	IC50 9.00
Melanocortin receptor 3	MC3R	agonist	Ki 8.90
Melanocortin receptor 4	MC4R	agonist	Ki 8.80
Adenosine deaminase	ADA	unknown	Ki 7.80

Regulatory approvals (2)

Date	Agency	Marketed as	Applicant	Orphan
2019-10-08	FDA	—	CLIVUNEL INC
2014-12-12	EMA	—	Clinuvel UK Limited	Yes

ATC classification

ATC code	Therapeutic hierarchy
D02BB02	DERMATOLOGICALS › EMOLLIENTS AND PROTECTIVES › PROTECTIVES AGAINST UV-RADIATION › Protectives against UV-radiation for systemic use

Chemical structure

• Molecular formula: C₇₈H₁₁₁N₂₁O₁₉
• Molecular weight: 1646.87 g/mol
• CAS number: 75921-69-6
• InChIKey: UAHFGYDRQSXQEB-PWPYQVNISA-N
• PubChem CID: 16197727

CCCC[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(C)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(N)=O

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Afamelanotide used for?

DrugCentral lists the following indications for Afamelanotide: Erythropoietic protoporphyria.

How does Afamelanotide work?

Its molecular targets in DrugCentral include Mc1r, Mc5r, Mc3r and MC1R (agonist).

When was Afamelanotide first approved?

Afamelanotide was first approved by the EMA in 2014.

What is the chemical formula of Afamelanotide?

Afamelanotide has the molecular formula C78H111N21O19 and a molecular weight of 1646.87 g/mol.

Sources

• DrugCentral drug card 4836 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL4297213 — compound record and bioactivity
• PubChem CID 16197727 — chemical identifiers
• DrugBank DB04931 — drug record
• FDA UNII QW68W3J66U — substance identity
• DailyMed: FDA labels for Afamelanotide — current prescribing information (label search)
• UniProt Q01726 (MC1R) — target protein
• UniProt P33032 (MC5R) — target protein
• UniProt P41968 (MC3R) — target protein
• UniProt P32245 (MC4R) — target protein
• UniProt P00813 (ADA) — target protein

How this page is built: methodology · editorial policy & corrections.